ten23 health AG

Based in Switzerland, ten23 health AG offers specialized contract development and manufacturing organization (CDMO) services primarily for the pharmaceutical and biotechnology sectors, focusing on the creation of safe and effective injectable medicines. Founded in 2021 and headquartered in Basel, Switzerland, ten23 health AG operates as a contract development and manufacturing organization (CDMO) dedicated to the pharmaceutical and biotech industries. The company was launched following an investment from 3i and its management in September 2021, though specific financial terms were not disclosed. The CEO, Hanns-Christian Mahler, leads the organization, which has made one notable deal to date, enhancing its operational capabilities.

ten23 health specializes in contract development and manufacturing organization (CDMO) services tailored for the pharmaceutical and biotechnology industries. The company's core product offerings include formulation, analytical and process development, sterile manufacturing (fill & finish), and testing for injectable treatments. These services are geared towards the development of differentiated, stable, and safe injectable medicines, addressing the needs of pharmaceutical companies and biotech start-ups globally. ten23 health operates from its state-of-the-art facilities in Basel and Visp, Switzerland, delivering innovative solutions to clients across various geographical markets, including Europe, North America, and Asia.

The clientele encompasses pharmaceutical companies seeking advanced manufacturing capabilities and regulatory compliance, ultimately aiming to enhance patient health and safety through the provision of high-quality injectable therapies. ten23 health generates revenue through a business model that emphasizes partnerships and B2B transactions with pharmaceutical and biotech companies. The company’s revenue structure is primarily based on service agreements for its CDMO offerings, which include specialized sterile manufacturing and quality control testing. These agreements may involve fixed project fees or variable pricing based on the scope and complexity of services provided.

For example, customers may engage ten23 health for non-GMP sterile filling services to expedite product development, followed by subsequent GMP-certified manufacturing for market-ready products. The strategic collaborations with companies like Ypsomed and SHL Medical further enhance ten23 health's market presence and revenue potential through integrated service offerings for drug delivery systems. In September 2021, ten23 health AG secured investment from 3i to bolster its operations and expand its service offerings. The company plans to utilize this funding to enhance the quality of its services, increase product development capacity, and accelerate growth in the global market.

Future plans include the design and launch of new products tailored to market needs, with specific geographic expansions targeted for Europe and North America by 2023.